Sanai Health Industry Group Company Limited provided group earnings guidance for the year ended December 31, 2023. For the period, the company expected that the Group will record a significant decrease in revenue and gross profit margin, which resulted in the substantial decrease in net profit attributable to the owner of the Company of not more than 40% as compared with that for the corresponding period of 2022. The significant decrease in revenue and gross profit margin was mainly attributable to the decrease in sales volume of self-manufactured pharmaceutical products and substantial increase in the general costs of traditional Chinese herb materials in the PRC during the Reporting Period.